TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00942500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-conditioning
Description: Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade \<2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
Study: NCT01662232

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green tea beverage
Study: NCT00451178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1.4 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 100 mg, oral, Days 1-5, six 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg, oral, Days 1-5, six 21-day cycles
Study: NCT00719875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: BID days -7, 1-7 and 15-21, 200 mg
Study: NCT03660176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: butyrate enemas + routine management
Description: 10ml/kg volume of butyrate enemas in addition to the colonic irrigations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine management
Description: the colonic irrigations
Study: NCT03254550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP Promotion Package
Description: A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge
Study: NCT00825721

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LiquiTears
Description: 4 drops applied daily for 360 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-KAD Ophthalmic Solution
Description: 4 drops applied daily for 360 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-KAD Ophthalmic Solution
Description: 4 drops applied daily for 360 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-KAD Ophthalmic Solution
Description: 4 drops applied daily for 360 days
Study: NCT02925728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger-Food
Description: Finger-Food at lunch and having diner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without Finger-Food
Description: Without finger-food
Study: NCT01313962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide-3 0.05 mg single dose
Description: Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide-3, 0.1 mg single dose
Description: Nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide-3, 0.2 mg single dose
Description: nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flufirvitide-3, 0.4 mg single dose
Description: Nasal spray

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal spray
Study: NCT01662232

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green tea extract

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00251147

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open acromioplasty with rotator cuff repair
Description: A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic acromioplasty with mini-open repair
Description: A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
Study: NCT00911391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler
Description: Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative fluid restriction
Description: Current best practice of avoiding fluid overload by intraoperative fluid restriction
Study: NCT01096511

Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
Study: NCT03433534

Intervention type: OTHER
Intervention: Pharmacokinetic of Nivolumab
Description: Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.
Study: NCT01042652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegarvir 400mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegarvir 400mg bid
Study: NCT04903366

Intervention type: DRUG
Intervention: Timolol Maleate
Description: timolol maleate 0.5% gel-forming solution

Intervention type: DRUG
Intervention: Timolol Maleate
Description: timolol maleate 0.5% gel-forming solution
Study: NCT03628729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embrace™ WetBond™ Pit & Fissure Sealant
Description: pit and fissure sealant that contain the precursor in the formation of hydroxyapatite which is Amorphous Calcium Phosphate (ACP) ,which has anti-cariogenic effect as well as remineralization potential as it contain bioactive material which stimulate crystal growth within the lesion by increasing the concentration of calcium and phosphate ions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA
Description: Fluoride releasing resin based pits and fissures sealant
Study: NCT00779831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg Pseudoephedrine hydrochloride extended release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 120 mg Pseudoephedrine hydrochloride extended release tablets
Study: NCT04366947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIO® (Intraosseous access)
Description: obtaining intravascular access using a ready intravenous NIO needle set

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care (Intravenous access)
Description: obtaining intravascular access using a standard intravenous cannula
Study: NCT01093092

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT01924117

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Linear Array HPV Genotyping assay
Description: All samples with the suspicion of squamous intraepithelial lesion were processed with the Linnear Array methodology to identify HPV genotypes
Study: NCT00195819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab (D2E7)
Description: Adalimumab 40 mg every other week (eow)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo every other week (eow)
Study: NCT00915629

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactibiane candisis 5M
Description: 2 gelules per day for 2 months then 1 gelule per day for 4 months
Study: NCT01093092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03873259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst Wave Lithotripsy
Description: Fragment upper urinary tract stones
Study: NCT03991676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values-Based Behavioral Treatment
Description: The values-based behavioral treatment will consist of a series of three, once-weekly weight loss workshops infused with techniques to elicit values clarification and awareness in moments of dietary decision-making, and to enhance autonomous motivation for behavior change.
Study: NCT04462432

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention.

Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention.
Study: NCT04778904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HBV
Description: Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HBV
Description: Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HBV
Description: Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HBV
Description: Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Human immunoglobulin G4 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Human immunoglobulin G4 monoclonal antibody
Study: NCT03498495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Monitoring Activity-restriction and Relaxation Training (SMART)
Description: SMART integrates real-time self-monitoring of symptoms and activities with interactive modules designed to increase self-efficacy through psychoeducation and training in problem solving/problem-focused coping strategies.
Study: NCT03003650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE TF™
Description: ACURATE TF™Transfemoral Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement .
Study: NCT03708302

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Unilateral serratus plane block
Description: Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane in 5 mls aliquot after aspiration. Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sternum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane slowly in 5 ml aliquots after aspiration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral serratus plane block
Description: Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane in 5 mls aliquot after aspiration. Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sternum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane slowly in 5 ml aliquots after aspiration.
Study: NCT01640483

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychodynamic techniques.
Description: the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychodynamic techniques.
Description: the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychodynamic techniques.
Description: the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
Study: NCT02540460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 800mg
Description: LCB01-0371 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 800mg BID
Description: LCB01-0371 800mg BID
Study: NCT00889473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larazotide acetate
Description: gelatin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gelatin capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten 900 mg
Description: gelatin capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gluten 900 mg
Description: gelatin capsule
Study: NCT03200509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Participants will receive a group exercise program, health coaching sessions and an activity monitor.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Participants will receive a group exercise program, sham health coaching sessions and a sham activity monitor.
Study: NCT01062165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Description: Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)
Study: NCT05702892

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA
Description: ELISA(enzyme-linked immunosorbent assay)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA
Description: ELISA(enzyme-linked immunosorbent assay)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA
Description: ELISA(enzyme-linked immunosorbent assay)
Study: NCT03301597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NLA101
Description: NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NLA101
Description: NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NLA101
Description: NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care (SOC) chemotherapy
Description: The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) chemotherapy
Description: The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) chemotherapy
Description: The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) chemotherapy
Description: The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
Study: NCT00811239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bungarus multicinctus-candidus Antivenom
Description: Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
Study: NCT00169273

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured behavioral weight loss group
Description: Structured group weight loss program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss and cognitive-behavioral depression group
Description: Structured group program for weight loss and depression
Study: NCT03810599

Intervention type: OTHER
Group type: OTHER
Intervention: Early cardiac rehabilitation
Description: This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.~For additional analysis there will be a comparison group that did not receive the intervention for practical reasons.
Study: NCT03341728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optical flow perturbations
Description: Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optical flow perturbations
Description: Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal walking
Description: Usual treadmill walking without optical flow perturbations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal walking
Description: Usual treadmill walking without optical flow perturbations
Study: NCT03137212

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: thrombolysis and PCI of A type
Description: STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: thrombolysis and PCI of B type
Description: STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
Study: NCT00548366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Description: 4 gram sodium diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium restriction
Description: 2 gram sodium diet
Study: NCT03878420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valeda PBM treatment
Description: The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Valeda Sham treatment
Description: The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.